EMA Authorised: Riltrava Aerosphere (Budesonide;formoterol fumarate dihydrate;glycopyrronium bromide) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Riltrava Aerosphere for chronic obstructive pulmonary disease as a triple-inhaler containing budesonide, formoterol, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide (BUDESONIDE)
• Formoterol fumarate dihydrate
• Glycopyrronium bromide (glycopyrronium bromide)
• Riltrava Aerosphere

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 30/09/2025